RYTM Stock Cash Flow Statements

Rhythm Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Rhythm Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

operating activities
net income	-46,632,000	-49,498,000	-43,292,000	-43,677,000	-32,261,000	-141,372,000	-41,633,000	-44,163,000	-46,703,000	-52,179,000	-42,493,000	-40,861,000	-45,001,000	-52,764,000	-42,866,000	-35,107,000	-35,389,000	43,750,000	-34,897,000	-33,818,000	-31,117,000	-34,164,000	-32,956,000	-36,003,000	-42,796,000	-28,974,000	-25,507,000	-17,686,000	-14,412,000	-16,459,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	15,880,000	12,862,000	10,556,000	11,001,000	10,358,000	7,767,000	8,674,000	8,612,000	8,891,000	6,376,000	5,287,000	4,796,000	5,137,000	4,611,000	4,676,000	5,268,000	5,669,000	5,191,000	4,257,000	4,695,000	3,028,000	5,475,000	2,924,000	3,035,000	3,272,000	2,644,000	2,023,000	1,893,000	1,516,000	958,000
depreciation and amortization	379,000	383,000	383,000	385,000	390,000	405,000	417,000	442,000	442,000	457,000	442,000	442,000	438,000	350,000	325,000	315,000	317,000	201,000	178,000	172,000	173,000	167,000	191,000	191,000	207,000	245,000	214,000	106,000	61,000	61,000
non-cash interest expense	5,818,000	5,408,000	8,413,000	4,203,000
non-cash accretion & amortization of short-term investments	-1,179,000	-1,787,000	-2,138,000	-2,465,000	-1,507,000	-2,055,000
non-cash rent expense	105,000	110,000	111,000	108,000	70,000	111,000	107,000	102,000	98,000	94,000	-69,000	-68,000	-65,000	-65,000	-65,000	-63,000	-61,000	-61,000			-58,000	-56,000	-58,000	8,000	151,000	102,000	84,000	17,000	-20,000	-20,000
change in fair value of embedded derivative liability	-500,000	80,000	-120,000	-510,000	-300,000	-490,000	-40,000	-130,000	30,000	-50,000
gain on settlement of forward contract			0	0
acquired ipr&d assets classified as investing activities			0	0	0	92,385,000	0	17,000	255,000	5,395,000
foreign currency (gain) loss
changes in operating assets and liabilities:
accounts receivable	-7,832,000	687,000	794,000	-1,708,000	-2,903,000	172,000	-326,000	-710,000	-5,714,000	-1,893,000
inventory	479,000	-575,000	-4,846,000	-1,901,000	-3,487,000	117,000	-862,000	-1,585,000	-690,000	-2,570,000
prepaid expenses and other current assets	-6,801,000	-3,204,000	-5,705,000	-106,000	2,708,000	-2,421,000	5,243,000	497,000	-2,678,000	-186,000	-744,000	-492,000	-1,530,000	950,000	-6,191,000	2,965,000	-3,025,000	1,651,000	-541,000	1,444,000	495,000	-847,000	-1,786,000	-544,000	-727,000	-3,321,000	-3,526,000	-1,927,000	-1,414,000	581,000
deferred revenue	0	-1,286,000					0	0	-142,000	-6,000	-7,080,000	-549,000
other long-term assets	5,424,000	102,000	4,786,000	908,000	1,054,000	1,195,000	-4,000	537,000	1,222,000	-99,000	1,000	-870,000	2,690,000	-6,661,000	-1,282,000
accounts payable, accrued expenses and other liabilities	13,255,000	-3,633,000	15,179,000	7,508,000	482,000	-1,251,000	4,858,000	4,087,000	661,000	5,167,000
net cash from operating activities	-23,313,000	-40,351,000	-18,845,000	-25,215,000	-29,076,000	-40,743,000	-29,383,000	-29,251,000	-41,090,000	-36,433,000	-34,000,000	-46,987,000	-38,809,000	-53,632,000	-40,472,000	-40,160,000	-31,840,000	-33,531,000	-29,123,000	-27,030,000	-29,729,000	-36,098,000	-32,221,000	-33,605,000	-25,546,000	-31,378,000	-20,983,000	-16,942,000	-12,480,000	-11,651,000
capex	0	0	0	0	0	0	1,000	-1,000	0	-47,000	1,000	-95,000	-60,000	-127,000	-68,000	-106,000	-248,000	-12,000	-84,000	0	0	0	0	-259,000	-2,315,000	-811,000	-395,000	-317,000	0	0
free cash flows	-23,313,000	-40,351,000	-18,845,000	-25,215,000	-29,076,000	-40,743,000	-29,382,000	-29,252,000	-41,090,000	-36,480,000	-33,999,000	-47,082,000	-38,869,000	-53,759,000	-40,540,000	-40,266,000	-32,088,000	-33,543,000	-29,207,000	-27,030,000	-29,729,000	-36,098,000	-32,221,000	-33,864,000	-27,861,000	-32,189,000	-21,378,000	-17,259,000	-12,480,000	-11,651,000
investing activities
purchases of short-term investments	-26,954,000	-33,521,000	-66,378,000	-135,623,000			-40,653,000	-169,187,000	-75,434,000	-69,644,000	-100,416,000	-101,081,000	-10,961,000	-39,479,000	-68,734,000	-93,769,000	-64,927,000	-297,542,000	-33,471,000	-9,985,000	-28,043,000	-15,370,000	-184,877,000	-41,073,000	-14,056,000	-55,819,000	-60,033,000	-168,150,000	-18,386,000	-2,023,000
maturities of short-term investments	80,989,000	58,333,000	87,535,000	45,305,000	57,750,000	70,050,000	63,292,000	74,500,000	124,500,000	92,675,000	59,640,000	61,479,000	51,000,000	112,128,000	69,050,000	156,655,000	83,700,000	51,842,000	95,442,000	45,025,000	60,904,000	44,243,000	45,750,000	82,803,000	62,516,000	80,171,000	72,703,000	32,000,000	34,833,000	22,630,000
acquisition of ipr&d assets			0	-500,000	0	-40,000,000
net cash from investing activities	54,035,000	24,812,000	21,157,000	-90,818,000	-8,562,000	30,050,000	22,640,000	-94,960,000	48,191,000	18,464,000	-40,775,000	-39,697,000	35,979,000	72,522,000	7,248,000	62,780,000	13,525,000	-145,712,000	61,887,000	34,910,000	32,861,000	28,873,000	-139,127,000	41,471,000	46,145,000	23,541,000	12,275,000	-136,467,000	16,437,000	20,607,000
financing activities
repayment of deferred royalty obligation	-4,332,000	-4,615,000	-3,808,000	-3,336,000	-2,973,000	-2,783,000				-1,351,000
proceeds from the exercise of stock options	3,443,000	2,226,000	2,990,000	5,231,000	1,402,000	6,353,000	4,997,000	1,577,000	341,000	553,000	5,889,000				105,000	180,000	383,000	3,466,000	420,000	501,000	183,000	383,000	611,000	434,000	498,000	21,000	174,000	1,308,000
proceeds from issuance of common stock from espp	0	854,000	0	597,000	0	673,000	0	388,000	0	665,000	0	227,000	0	399,000	0	233,000	0	388,000	0	198,000	0	324,000	0	263,000	0	295,000
proceeds from series a preferred stock, net of issuance costs			0	0
proceeds from atm equity offering	0	34,034,000
net cash from financing activities	-889,000	32,499,000	38,328,000	2,492,000	146,179,000	4,243,000	2,423,000	73,043,000	-965,000	-133,000	17,365,000	158,564,000	37,500,000	399,000	100,000	413,000	383,000	165,585,000	420,000	699,000	183,000	707,000	161,963,000	697,000	498,000	316,000	153,000	1,173,000
effect of exchange rates on cash	-279,000	-2,000	977,000	-603,000	-301,000	-71,000	-192,000	77,000	-113,000	86,000
net increase in cash, cash equivalents and restricted cash	29,554,000	16,958,000	41,618,000	-114,145,000			-4,512,000	-51,091,000	6,023,000	-18,016,000	-57,410,000	71,880,000	34,670,000	19,289,000	-33,124,000				33,184,000	8,579,000	3,315,000	-6,518,000	-9,385,000	8,563,000	21,097,000	-7,521,000	-8,555,000	-152,236,000	167,317,000	8,956,000
cash, cash equivalents and restricted cash at beginning of period	0	89,601,000	0	0	0	60,409,000	0	0	0	128,005,000	0	0	0	59,576,000	0	0	0	101,257,000	0					0	0	49,943,000	0	0
cash, cash equivalents and restricted cash at end of period	29,554,000	106,559,000	41,618,000	-114,145,000	108,240,000	53,888,000	-4,512,000	-51,091,000	6,023,000	109,989,000	-57,410,000	71,880,000	34,670,000	78,865,000	-33,124,000	23,033,000	-17,932,000	87,599,000	33,184,000					8,563,000	21,097,000	42,422,000	-8,555,000	-152,236,000
supplemental disclosure of non-cash investing and financing activities:
non-current liability issued in exchange for the acquisition of ipr&d			0	0	0	33,669,000
issuance of common stock in exchange for ipr&d			0	0	0	18,716,000
accretion of preferred stock dividends	1,349,000	1,322,000	1,339,000	1,329,000
loss on rarestone equity investment											0
payment of milestone obligation under license agreement											0
purchases of property and equipment							1,000	-1,000	0	-47,000	1,000	-95,000	-60,000	-127,000	-68,000	-106,000	-248,000	-12,000	-84,000				0	-259,000	-2,315,000	-811,000
net proceeds from issuance of common stock							0				14,138,000				-5,000	0	0	161,731,000									-21,000	-135,000
proceeds from royalty financing agreement, net of issuance costs							0
non-cash accretion of other current liability
non-cash accretion of non-current liability					998,000	929,000
holdback payable associated with acquisition of ipr&d assets, in accrued expenses
transaction costs associated with acquisition of ipr&d assets, in accounts payable
non-cash interest expense and amortization of debt issuance costs						4,009,000	4,018,000	3,148,000	3,133,000	3,061,000	3,199,000
unrealized loss on short-term investments						-244,000
net decrease in cash, cash equivalents and restricted cash						-6,521,000											-17,932,000	-13,658,000
supplemental disclosure of non-cash investing activities:
gain on sale of priority review voucher															0	0	0	-100,000,000
proceeds from sale of priority review voucher															0	0	0	100,000,000
proceeds from out-license agreement
acquisition of ipr&d assets, including transaction costs							0	-272,000	-875,000	-4,520,000

repayments on deferred royalty obligation								-2,167,000
deferred financing costs in accrued expenses												-354,000
unrealized gain on short-term investments
holdback payable associated with the acquisition, in accrued expenses									0	500,000
transaction costs associated with the acquisition, in accounts payable									-120,000	375,000
accounts payable, accrued expenses and other current liabilities											15,712,000	-12,569,000	-1,547,000	-53,000	12,920,000	5,990,000	5,671,000	-6,269,000	1,941,000	536,000	-2,250,000	-6,673,000	-536,000	-1,230,000	14,347,000	-2,074,000	5,729,000	655,000	1,789,000	-1,220,000
deferred tax provision																-8,995,000	-5,022,000	22,006,000
proceeds from royalty financing agreement												37,500,000
supplemental disclosures:
amortization of debt issuance costs
milestone obligation under license agreement															0	0
adjustments to reconcile net income to cash from operating activities:
non-cash research and development license expense																											0	0	0	4,448,000
deferred rent
tenant improvement allowance																							0
deferred rent expense
cash, cash equivalents and restricted cash at beginning of year																					0	62,697,000								34,461,000
cash, cash equivalents and restricted cash at end of year																					3,315,000	56,179,000								43,417,000
mark to market revaluation of series a investor instrument
deferred issuance costs
due to related party
net proceeds from issuance of series a convertible preferred stock
deferred grant income
due to related parties
purchases of property, plant and equipment																											-395,000	-317,000
net cash provided by:
net increase in cash and cash equivalents																															6,322,000
cash and cash equivalents at beginning of period
cash and cash equivalents at end of period

We provide you with 20 years of cash flow statements for Rhythm Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Rhythm Pharmaceuticals stock. Explore the full financial landscape of Rhythm Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Rhythm Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.